A carregar...

IL10RA modulates crizotinib sensitivity in NPM1-ALK(+) anaplastic large cell lymphoma

Anaplastic large cell lymphoma (ALCL) is a T-cell malignancy predominantly driven by a hyperactive anaplastic lymphoma kinase (ALK) fusion protein. ALK inhibitors, such as crizotinib, provide alternatives to standard chemotherapy with reduced toxicity and side effects. Children with lymphomas driven...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Prokoph, Nina, Probst, Nicola A., Lee, Liam C., Monahan, Jack M., Matthews, Jamie D., Liang, Huan-Chang, Bahnsen, Klaas, Montes-Mojarro, Ivonne A., Karaca-Atabay, Elif, Sharma, Geeta G., Malik, Vikas, Larose, Hugo, Forde, Sorcha D., Ducray, Stephen P., Lobello, Cosimo, Wang, Qi, Luan, Shi-Lu, Pospíšilová, Šárka, Gambacorti-Passerini, Carlo, Burke, G. A. Amos, Pervez, Shahid, Attarbaschi, Andishe, Janíková, Andrea, Pacquement, Hélène, Landman-Parker, Judith, Lambilliotte, Anne, Schleiermacher, Gudrun, Klapper, Wolfram, Jauch, Ralf, Woessmann, Wilhelm, Vassal, Gilles, Kenner, Lukas, Merkel, Olaf, Mologni, Luca, Chiarle, Roberto, Brugières, Laurence, Geoerger, Birgit, Barbieri, Isaia, Turner, Suzanne D.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2020
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7530646/
https://ncbi.nlm.nih.gov/pubmed/32573700
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019003793
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!